Editorial
doi: 10.1200/JCO.2008.18.5447.
Epub 2008 Oct 14.
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas
- PMID: 18854559
- PMCID: PMC2652089
- DOI: 10.1200/JCO.2008.18.5447
Item in Clipboard
Editorial
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas
J Clin Oncol.
.
No abstract available
Comment in
-
Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan.J Clin Oncol. 2009 Mar 1;27(7):1145-6; author reply 1146. doi: 10.1200/JCO.2008.20.8769. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171699 No abstract available.
Comment on
-
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854568 Clinical Trial.
-
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
Similar articles
-
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.N Engl J Med. 2008 Aug 7;359(6):613-26. doi: 10.1056/NEJMra0708875. N Engl J Med. 2008. PMID: 18687642 Review. No abstract available.
-
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854568 Clinical Trial.
-
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
-
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1274-87. doi: 10.1016/j.ijrobp.2004.02.065. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275710 Review.
-
[Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].MMW Fortschr Med. 2004 Apr 8;146(15):66. MMW Fortschr Med. 2004. PMID: 15373026 German. No abstract available.
Cited by
-
Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.Cancer Manag Res. 2009 Oct 21;1:131-6. doi: 10.2147/cmr.s6765. Cancer Manag Res. 2009. PMID: 21188131 Free PMC article.
-
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Blood. 2009 Apr 23;113(17):3891-5. doi: 10.1182/blood-2008-11-188896. Epub 2009 Jan 30. Blood. 2009. PMID: 19182204 Free PMC article.
-
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.Haematologica. 2014 Nov;99(11):1738-45. doi: 10.3324/haematol.2014.112110. Epub 2014 Aug 22. Haematologica. 2014. PMID: 25150258 Free PMC article. Clinical Trial.
-
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Cancer. 2010 Feb 15;116(4 Suppl):1134-45. doi: 10.1002/cncr.24802. Cancer. 2010. PMID: 20127947 Free PMC article.
-
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.Bioconjug Chem. 2010 Jul 21;21(7):1225-38. doi: 10.1021/bc100030q. Bioconjug Chem. 2010. PMID: 20597486 Free PMC article.
References
-
- Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol doi:10.1200/JCO.2008.17.2015 [epub ahead of print on October 13, 2008] - DOI - PubMed
-
- Devizzi L, Guidetti A, Tarella C, et al: High-dose yttrium-90–ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol doi:10.1200/JCO.2008.16.8294 [epub ahead of print on October 13, 2008] - DOI - PubMed
-
- DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246-3256, 1998 - PubMed
-
- Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993 - PubMed
-
- Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
